Alza Corporation

Vivus, Inc.

Other

Durect Corporation

Virgil A. Place

Robert M. Gale

Randall G. Berggren

Robert M Gale

David J Enscore

Randall G Berggren

Diane E Nedberge

Su Il Yum

Eun Soo Lee

Jay Douglas Audett

Linda E Atkinson

Melinda K Nelson

Michel J N Cormier

Virgil A Place

John W Shell

Paul B Foreman

Patricia S Campbell

Eric N Silverberg

Allison Luciano

Terry L Burkoth

James L Osborne

Jane E Shaw

Yu-Ling Cheng

Jianye Wen

Lina T Taskovich

Harold F Sanders

Tyler Watanabe

Eli J Goldman

Edna Sugihara

Joseph B Phipps

Suneel K Gupta

Rama V Padmanabhan

Thomas M Stein

Jane Stepic

Felix T Theeuwes

Patrick S Wong

Alejandro C Zaffaroni

Lothar W Kleiner

John Urquhart

Guohua Chen

Keith E Dionne

Paul R Houston

Richard D Hamlin

William W Van Osdol

Shaoling Li

David L Rivera

Russell D Beste

Gilbert T Tong

John T Dunn

Shari B Libicki

Victor Goetz

Monique Ben-Dor

Stephen S Hwang

Subramanian S Venkatraman

Michael J N Cormier

Andrew G Scott

Donna D Causey

Su Ll Yum

Nancy Keller

Arnold Kaufman

A transdermal nicotine salt delivery system to an individual. The system has a high nicotine salt loading to effect therapeutic flux rate. Acrylate polymeric drug reservoir with the high nicotine salt dissolved therein provides desirable adhesive characteristics and effective transdermal therapeutic properties.

Transdermal nicotine salt delivery system

A polyacrylate formulation suitable for delivery of drug to through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives.

High enhancer-loading polyacrylate formulation for transdermal applications

A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%.

Transparent transdermal nicotine delivery devices

Method of making a high enhancer-loading polyacrylate formulation for transdermal applications

A transdermal analgesic system having reduced potential for abuse, wherein the system provides for the controlled release of the antagonist at a rate sufficient to provide an abuse limiting release rate ratio of the antagonist to the analgesic when the dosage form is subject to abuse is disclosed.

Transdermal analgesic systems with reduced abuse potential

A polyacrylate formulation suitable for delivery of drug through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives.

An apparatus for transdermally delivering a nicotine-based agent to a tobacco or nicotine user comprising a microprojection member having a plurality of microprojections that are adapted to pierce the stratum corneum of the tobacco user, the microprojection member having a biocompatible coating disposed thereon that includes a nicotine-based agent.

Method and apparatus for reducing the incidence of tobacco use

Composition of matter for application to a body surface or membrane to administer warfarin by permeation through the body surface or membrane, the composition comprising warfarin to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the warfarin or warfarin and enhancer composition and methods for the transdermal administration of the warfarin and warfarin/enhancer composition.

Transdermal warfarin system

Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.

Formulations for the administration of fluoxetine

Growing community of inventors

Los Altos, CA, United States of America

Robert M Gale